Pfizer bags a Langer platform, buys Bind assets with a $40M bid
In the end, Pfizer saw the most value in Bind Therapeutics’ platform technology. Already partnered on new products, Pfizer has come up with a winning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
